Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

T Cell Types and Functions01:24

T Cell Types and Functions

2.1K
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
2.1K
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

12.0K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
12.0K
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

484
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
484
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

483
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
483
Inflammatory Response01:28

Inflammatory Response

15.9K
An inflammatory response is a localized, nonspecific immune reaction that occurs when a tissue is injured. It is characterized by redness, swelling, heat, and pain, which are commonly called the cardinal signs and symptoms of inflammation. Inflammation can sometimes result in a loss of function.
Inflammation can be triggered by various stimuli, such as impact, abrasion, chemical irritation, infections, and extreme hot or cold temperatures. These can damage cells and connective tissue fibers,...
15.9K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Spondyloarthritis and inflammatory bowel disease: towards a more severe and refractory disease phenotype.

EULAR rheumatology open·2026
Same author

Discrepancies in the assessment of axial spondyloarthritis between patients and rheumatologists: what does this mean?

Clinical rheumatology·2026
Same author

Late-onset psoriatic arthritis: A separate entity.

Joint bone spine·2026
Same author

Bacterial translocation and intestinal permeability in early axial spondyloarthritis association with 5-year outcomes: insights from the DESIR cohort.

Rheumatology (Oxford, England)·2026
Same author

Clinical Images: A painful bipartite patella.

Arthritis & rheumatology (Hoboken, N.J.)·2026
Same author

Dubious benefit of three injections of botulinum toxin in refractory chronic neck pain: Retrospective data on 22 patients with a 9-month follow-up.

Joint bone spine·2026

Related Experiment Video

Updated: Jan 14, 2026

Author Spotlight: Evaluating Traditional Chinese Therapy for Ankylosing Spondylitis in Mice
04:47

Author Spotlight: Evaluating Traditional Chinese Therapy for Ankylosing Spondylitis in Mice

Published on: October 27, 2023

1.7K

IL-33 in Spondyloarthritis, the missing key.

Frank Verhoeven1, Dalil Hannani2, Céline Demougeot3

  • 1Université Marie et Louis Pasteur, EFS, INSERM UMR 1098 RIGHT, Besançon F-25000, France; Rhumatologie, CHU de Besançon, Besançon, France; Univ. Grenoble Alpes, CNRS, UMR 5525, VetAgro Sup, Grenoble INP, TIMC, 38000 Grenoble, France.

Autoimmunity Reviews
|October 24, 2025
PubMed
Summary
This summary is machine-generated.

Interleukin-33 (IL-33) is implicated in spondyloarthritis (SpA) inflammation and bone changes. Targeting the IL-33/ST2 pathway shows promise for treating SpA and preventing joint damage.

Keywords:
IL-33Spondyloarthritis

More Related Videos

Adoptive Transfer of IL-33-Stimulated Macrophages into Bleomycin-Induced Mouse Models to Study Their Effect on Idiopathic Pulmonary Fibrosis In Vivo
06:29

Adoptive Transfer of IL-33-Stimulated Macrophages into Bleomycin-Induced Mouse Models to Study Their Effect on Idiopathic Pulmonary Fibrosis In Vivo

Published on: May 5, 2023

3.0K
Isolation and Th17 Differentiation of Naïve CD4 T Lymphocytes
12:59

Isolation and Th17 Differentiation of Naïve CD4 T Lymphocytes

Published on: September 26, 2013

35.4K

Related Experiment Videos

Last Updated: Jan 14, 2026

Author Spotlight: Evaluating Traditional Chinese Therapy for Ankylosing Spondylitis in Mice
04:47

Author Spotlight: Evaluating Traditional Chinese Therapy for Ankylosing Spondylitis in Mice

Published on: October 27, 2023

1.7K
Adoptive Transfer of IL-33-Stimulated Macrophages into Bleomycin-Induced Mouse Models to Study Their Effect on Idiopathic Pulmonary Fibrosis In Vivo
06:29

Adoptive Transfer of IL-33-Stimulated Macrophages into Bleomycin-Induced Mouse Models to Study Their Effect on Idiopathic Pulmonary Fibrosis In Vivo

Published on: May 5, 2023

3.0K
Isolation and Th17 Differentiation of Naïve CD4 T Lymphocytes
12:59

Isolation and Th17 Differentiation of Naïve CD4 T Lymphocytes

Published on: September 26, 2013

35.4K

Area of Science:

  • Immunology
  • Rheumatology
  • Pathophysiology

Background:

  • Interleukin-33 (IL-33) is an alarmin released during tissue damage, increasingly linked to inflammatory diseases like spondyloarthritis (SpA).
  • The IL-33/ST2 pathway influences immune cell activation, including type 2 innate lymphoid cells, Th17 responses, and macrophage polarization, contributing to SpA pathogenesis.
  • IL-33 plays a role in both musculoskeletal (enthesitis, synovitis, axial inflammation) and extra-articular (gut, skin, eye) manifestations of SpA.

Purpose of the Study:

  • To review the emerging role of the IL-33/ST2 pathway in the pathophysiology of spondyloarthritis.
  • To discuss the therapeutic potential of targeting IL-33 for SpA treatment, including its impact on inflammation and bone metabolism.

Main Methods:

  • Review of preclinical studies and existing literature on the IL-33/ST2 axis in spondyloarthritis.
  • Analysis of IL-33's dual role in inflammation and bone metabolism within the context of SpA.

Main Results:

  • Preclinical studies targeting the IL-33/ST2 axis demonstrate reduced arthritis severity, joint damage, and inflammation.
  • IL-33 exhibits a dual role, potentially inhibiting osteoclast differentiation or promoting pathological bone formation via pro-osteogenic macrophages.
  • IL-33 modulation offers a potential strategy to control inflammation and influence structural outcomes, including new bone formation in SpA.

Conclusions:

  • The IL-33/ST2 pathway is a significant factor in SpA development and progression.
  • Targeting IL-33 presents a promising therapeutic avenue, potentially complementing existing treatments like anti-TNFα and anti-IL-17 therapies.
  • Modulating IL-33 could offer a dual benefit in SpA by reducing inflammation and altering bone remodeling processes.